Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Trimodal Therapy for Patients With Anaplastic Thyroid Cancer
08/19/2025
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460 patients with anaplastic thyroid cancer compared outcomes by the number of treatment modalities used. Which of the following statements best illustrates study findings?
A retrospective analysis of 3460...
08/19/2025
Oncology
Quiz
Neoadjuvant Pembrolizumab Plus Dabrafenib and Trametinib for Patients With BRAF V600E-Mutated Anaplastic Thyroid Cancer
07/29/2025
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a phase 2 study, neoadjuvant pembrolizumab with dabrafenib and trametinib enabled surgical resection among patients with BRAF V600E-mutated anaplastic thyroid cancer, leading to improved progression-free survival...
True or False: According to a...
07/29/2025
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted FDA Approval for DTC?
12/06/2021
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently approved by the FDA for locally advanced or metastatic differentiated thyroid cancer?
Which treatment was recently...
12/06/2021
Oncology
Test Your Knowledge
Quiz: Lenvatinib Monotherapy for Patients with Anaplastic Thyroid Cancer
09/01/2021
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a phase 2 trial suggest lenvatinib monotherapy may be an effective treatment for anaplastic thyroid cancer.
True or false: Results from a...
09/01/2021
Oncology
Quiz
Quiz: Efficacy of Vandetanib, Cabozantinib for Advanced MTCctive in Treating Advanced MTC?
06/21/2021
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a...
06/21/2021
Oncology
Quiz
Quiz: Efficacy of Vandetanib, Cabozantinib for Advanced MTCctive in Treating Advanced MTC?
06/21/2021
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a real-world study showed that vandetanib and cabozantinib were ineffective for the treatment of patients with advanced MTC.
True or False: Results from a...
06/21/2021
Oncology
Test Your Knowledge
Quiz: Does Artificial LAN Increase the Risk of Thyroid Cancer?
04/05/2021
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN may increase the risk of thyroid cancer?
True or false: Artificial LAN...
04/05/2021
Oncology
Test Your Knowledge
Quiz: Has Selpercatinib Been Proven Effective in Thyroid Cancer?
02/01/2021
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial found Selpercatinib to be ineffective in patients with RET-mutant medullary thyroid cancer.
True or false: A phase 1/2 trial...
02/01/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment Was Recently Granted Accelerated Approval in RET-Altered Thyroid Cancers?
01/11/2021
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
Which of the following...
01/11/2021
Oncology
Test Your Knowledge
Quiz: The FDA Approved Pralsetinib For Which Type of Thyroid Cancer?
01/08/2021
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved pralsetinib for RET-altered _______ thyroid cancer.
The FDA recently approved...
01/08/2021
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use